Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 270

1.

Determination of Pharmacodynamic Target Exposures for Rezafungin against Candida tropicalis and Candida dubliniensis in the Neutropenic Mouse Disseminated Candidiasis Model.

Lepak AJ, Zhao M, Andes DR.

Antimicrob Agents Chemother. 2019 Sep 3. pii: AAC.01556-19. doi: 10.1128/AAC.01556-19. [Epub ahead of print]

PMID:
31481440
2.

Characterization of an Uncinocarpus reesii-expressed recombinant tube precipitin antigen of Coccidioides posadasii for serodiagnosis.

Yu JJ, Holbrook E, Liao YR, Zarnowski R, Andes DR, Wheat LJ, Malo J, Hung CY.

PLoS One. 2019 Aug 14;14(8):e0221228. doi: 10.1371/journal.pone.0221228. eCollection 2019.

3.

The Candida albicans biofilm gene circuit modulated at the chromatin level by a recent molecular histone innovation.

Rai LS, Singha R, Sanchez H, Chakraborty T, Chand B, Bachellier-Bassi S, Chowdhury S, d'Enfert C, Andes DR, Sanyal K.

PLoS Biol. 2019 Aug 9;17(8):e3000422. doi: 10.1371/journal.pbio.3000422. eCollection 2019 Aug.

4.

A targeted fungal prophylaxis protocol with static dosed fluconazole significantly reduces invasive fungal infection after liver transplantation.

Jorgenson MR, Descourouez JL, Marka NA, Leverson GE, Smith JA, Andes DR, Fernandez LA, Foley DP.

Transpl Infect Dis. 2019 Aug 7:e13156. doi: 10.1111/tid.13156. [Epub ahead of print]

PMID:
31390109
5.

In vivo Pharmacodynamic Target Determination for Delafloxacin against Klebsiella pneumoniae and Pseudomonas aeruginosa in the Neutropenic Murine Pneumonia Model.

Zhao M, Lepak AJ, Marchillo K, Andes DR.

Antimicrob Agents Chemother. 2019 Jul 22. pii: AAC.01131-19. doi: 10.1128/AAC.01131-19. [Epub ahead of print]

PMID:
31332063
6.

Impact of triazole therapeutic drug monitoring availability and timing.

McCreary EK, Bayless M, Van AP, Lepak AJ, Wiebe DA, Schulz LT, Andes DR.

Antimicrob Agents Chemother. 2019 Jul 22. pii: AAC.01245-19. doi: 10.1128/AAC.01245-19. [Epub ahead of print]

PMID:
31332058
7.

Small-Molecule Morphogenesis Modulators Enhance the Ability of 14-Helical β-Peptides To Prevent Candida albicans Biofilm Formation.

Rodríguez López AL, Lee MR, Wang NB, Dunn KK, Sanchez H, Raman N, Andes DR, Lynn DM, Palecek SP.

Antimicrob Agents Chemother. 2019 Aug 23;63(9). pii: e02653-18. doi: 10.1128/AAC.02653-18. Print 2019 Sep.

PMID:
31209011
8.

Pharmacokinetic/Pharmacodynamic Evaluation of Solithromycin against Streptococcus pneumoniae Using Data from a Neutropenic Murine Lung Infection Model.

Okusanya OO, Forrest A, Bhavnani SM, Fernandes P, Ambrose PG, Andes DR.

Antimicrob Agents Chemother. 2019 Jul 25;63(8). pii: e02606-18. doi: 10.1128/AAC.02606-18. Print 2019 Aug.

PMID:
31182534
9.

In Vivo Pharmacodynamics of Omadacycline against Staphylococcus aureus in the Neutropenic Murine Thigh Infection Model.

Lepak AJ, Zhao M, Marchillo K, VanHecker J, Andes DR.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00624-19. doi: 10.1128/AAC.00624-19. Print 2019 Jul.

PMID:
31036691
10.

Bacterial Infections in the Stem Cell Transplant Recipient and Hematologic Malignancy Patient.

Misch EA, Andes DR.

Infect Dis Clin North Am. 2019 Jun;33(2):399-445. doi: 10.1016/j.idc.2019.02.011. Review.

PMID:
31005135
11.

In vivo pharmacodynamics of lefamulin, the first systemic pleuromutilin for human use, in a neutropenic murine thigh infection model.

Wicha WW, Craig WA, Andes D.

J Antimicrob Chemother. 2019 Apr 1;74(Supplement_3):iii5-iii10. doi: 10.1093/jac/dkz085.

12.

The antimicrobial potential of Streptomyces from insect microbiomes.

Chevrette MG, Carlson CM, Ortega HE, Thomas C, Ananiev GE, Barns KJ, Book AJ, Cagnazzo J, Carlos C, Flanigan W, Grubbs KJ, Horn HA, Hoffmann FM, Klassen JL, Knack JJ, Lewin GR, McDonald BR, Muller L, Melo WGP, Pinto-Tomás AA, Schmitz A, Wendt-Pienkowski E, Wildman S, Zhao M, Zhang F, Bugni TS, Andes DR, Pupo MT, Currie CR.

Nat Commun. 2019 Jan 31;10(1):516. doi: 10.1038/s41467-019-08438-0.

13.

APX001 Pharmacokinetic/Pharmacodynamic Target Determination against Aspergillus fumigatus in an In Vivo Model of Invasive Pulmonary Aspergillosis.

Zhao M, Lepak AJ, Marchillo K, Vanhecker J, Sanchez H, Ambrose PG, Andes DR.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02372-18. doi: 10.1128/AAC.02372-18. Print 2019 Apr.

PMID:
30670426
14.

Conserved Role for Biofilm Matrix Polysaccharides in Candida auris Drug Resistance.

Dominguez EG, Zarnowski R, Choy HL, Zhao M, Sanchez H, Nett JE, Andes DR.

mSphere. 2019 Jan 2;4(1). pii: e00680-18. doi: 10.1128/mSphereDirect.00680-18.

15.

Exploiting the vulnerable active site of a copper-only superoxide dismutase to disrupt fungal pathogenesis.

Robinett NG, Culbertson EM, Peterson RL, Sanchez H, Andes DR, Nett JE, Culotta VC.

J Biol Chem. 2019 Feb 22;294(8):2700-2713. doi: 10.1074/jbc.RA118.007095. Epub 2018 Dec 28.

PMID:
30593499
16.

Time for Precision: A World Without Susceptibility Breakpoints.

Bader JC, Lakota EA, Andes DR, Rubino CM, Ambrose PG, Bhavnani SM.

Open Forum Infect Dis. 2018 Oct 31;5(12):ofy282. doi: 10.1093/ofid/ofy282. eCollection 2018 Dec.

17.

Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against Staphylococcus aureus and Streptococcus pneumoniae.

Lepak AJ, Zhao M, Liu Q, Wang P, Wang Y, Bader JC, Ambrose PG, Andes DR.

Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e02404-18. doi: 10.1128/AAC.02404-18. Print 2019 Mar.

18.

Candida-streptococcal interactions in biofilm-associated oral diseases.

Koo H, Andes DR, Krysan DJ.

PLoS Pathog. 2018 Dec 13;14(12):e1007342. doi: 10.1371/journal.ppat.1007342. eCollection 2018 Dec. Review. No abstract available.

19.

Variability and exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases.

Kaindl T, Andes D, Engelhardt M, Saulay M, Larger P, Groll AH.

J Antimicrob Chemother. 2019 Mar 1;74(3):761-767. doi: 10.1093/jac/dky463.

20.

Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials.

Andes DR, Ghannoum MA, Mukherjee PK, Kovanda LL, Lu Q, Jones ME, Santerre Henriksen A, Lademacher C, Hope WW.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01634-18. doi: 10.1128/AAC.01634-18. Print 2019 Jan.

21.

How Clean Is the Linen at My Hospital? The Mucorales on Unclean Linen Discovery Study of Large United States Transplant and Cancer Centers.

Sundermann AJ, Clancy CJ, Pasculle AW, Liu G, Cumbie RB, Driscoll E, Ayres A, Donahue L, Pergam SA, Abbo L, Andes DR, Chandrasekar P, Galdys AL, Hanson KE, Marr KA, Mayer J, Mehta S, Morris MI, Perfect J, Revankar SG, Smith B, Swaminathan S, Thompson GR, Varghese M, Vazquez J, Whimbey E, Wingard JR, Nguyen MH.

Clin Infect Dis. 2019 Feb 15;68(5):850-853. doi: 10.1093/cid/ciy669.

PMID:
30299481
22.

Candida albicans biofilm-induced vesicles confer drug resistance through matrix biogenesis.

Zarnowski R, Sanchez H, Covelli AS, Dominguez E, Jaromin A, Bernhardt J, Mitchell KF, Heiss C, Azadi P, Mitchell A, Andes DR.

PLoS Biol. 2018 Oct 8;16(10):e2006872. doi: 10.1371/journal.pbio.2006872. eCollection 2018 Oct.

23.

Has the Optimal Therapy for Invasive Candidiasis Now Been Defined?

Andes D.

Clin Infect Dis. 2019 May 30;68(12):1990-1992. doi: 10.1093/cid/ciy830. No abstract available.

PMID:
30289475
24.

Pharmacodynamic Evaluation of Rezafungin (CD101) against Candida auris in the Neutropenic Mouse Invasive Candidiasis Model.

Lepak AJ, Zhao M, Andes DR.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01572-18. doi: 10.1128/AAC.01572-18. Print 2018 Nov.

25.

Pharmacokinetics of extended dose intervals of micafungin in haematology patients: optimizing antifungal prophylaxis.

Muilwijk EW, Maertens JA, van der Velden WJFM, Ter Heine R, Colbers A, Burger DM, Andes D, Theunissen K, Blijlevens NMA, Brüggemann RJM.

J Antimicrob Chemother. 2018 Nov 1;73(11):3095-3101. doi: 10.1093/jac/dky324.

PMID:
30137340
26.

Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms.

Van Dijck P, Sjollema J, Cammue BP, Lagrou K, Berman J, d'Enfert C, Andes DR, Arendrup MC, Brakhage AA, Calderone R, Cantón E, Coenye T, Cos P, Cowen LE, Edgerton M, Espinel-Ingroff A, Filler SG, Ghannoum M, Gow NAR, Haas H, Jabra-Rizk MA, Johnson EM, Lockhart SR, Lopez-Ribot JL, Maertens J, Munro CA, Nett JE, Nobile CJ, Pfaller MA, Ramage G, Sanglard D, Sanguinetti M, Spriet I, Verweij PE, Warris A, Wauters J, Yeaman MR, Zaat SAJ, Thevissen K.

Microb Cell. 2018 Jun 14;5(7):300-326. doi: 10.15698/mic2018.07.638. Review.

27.

In Vivo Pharmacodynamic Characterization of a Novel Odilorhabdin Antibiotic, NOSO-502, against Escherichia coli and Klebsiella pneumoniae in a Murine Thigh Infection Model.

Zhao M, Lepak AJ, Marchillo K, VanHecker J, Andes DR.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e01067-18. doi: 10.1128/AAC.01067-18. Print 2018 Sep.

28.

Topical delivery of ebselen encapsulated in biopolymeric nanocapsules: drug repurposing enhanced antifungal activity.

Jaromin A, Zarnowski R, Piętka-Ottlik M, Andes DR, Gubernator J.

Nanomedicine (Lond). 2018 May;13(10):1139-1155. doi: 10.2217/nnm-2017-0337. Epub 2018 Jun 6.

29.

Pharmacokinetics-pharmacodynamics, computer decision support technologies, and antimicrobial stewardship: the compass and rudder.

Owens RC Jr, Bulik CC, Andes DR.

Diagn Microbiol Infect Dis. 2018 Aug;91(4):371-382. doi: 10.1016/j.diagmicrobio.2018.03.015. Epub 2018 Apr 13. Review.

PMID:
29776710
30.

A Mycoses Study Group International Prospective Study of Phaeohyphomycosis: An Analysis of 99 Proven/Probable Cases.

Revankar SG, Baddley JW, Chen SC, Kauffman CA, Slavin M, Vazquez JA, Seas C, Morris MI, Nguyen MH, Shoham S, Thompson GR 3rd, Alexander BD, Simkins J, Ostrosky-Zeichner L, Mullane K, Alangaden G, Andes DR, Cornely OA, Wahlers K, Lockhart SR, Pappas PG.

Open Forum Infect Dis. 2017 Sep 26;4(4):ofx200. doi: 10.1093/ofid/ofx200. eCollection 2017 Fall.

31.

Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials.

Andes D, Kovanda L, Desai A, Kitt T, Zhao M, Walsh TJ.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00585-18. doi: 10.1128/AAC.00585-18. Print 2018 Jul.

32.

Bacterial-derived exopolysaccharides enhance antifungal drug tolerance in a cross-kingdom oral biofilm.

Kim D, Liu Y, Benhamou RI, Sanchez H, Simón-Soro Á, Li Y, Hwang G, Fridman M, Andes DR, Koo H.

ISME J. 2018 Jun;12(6):1427-1442. doi: 10.1038/s41396-018-0113-1. Epub 2018 Apr 18.

33.

Conservation and Divergence in the Candida Species Biofilm Matrix Mannan-Glucan Complex Structure, Function, and Genetic Control.

Dominguez E, Zarnowski R, Sanchez H, Covelli AS, Westler WM, Azadi P, Nett J, Mitchell AP, Andes DR.

MBio. 2018 Apr 3;9(2). pii: e00451-18. doi: 10.1128/mBio.00451-18.

34.

Identification of the In Vivo Pharmacokinetics and Pharmacodynamic Driver of Iclaprim.

Park JH, Craig W, Marchillo K, Huang DB, Andes DR.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02550-17. doi: 10.1128/AAC.02550-17. Print 2018 Apr.

35.

In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model.

Zhao M, Lepak AJ, VanScoy B, Bader JC, Marchillo K, Vanhecker J, Ambrose PG, Andes DR.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02542-17. doi: 10.1128/AAC.02542-17. Print 2018 Apr.

36.

We can do better: a fresh look at echinocandin dosing.

Bader JC, Bhavnani SM, Andes DR, Ambrose PG.

J Antimicrob Chemother. 2018 Mar 1;73(3):831. doi: 10.1093/jac/dky013. No abstract available.

PMID:
29340605
37.

We can do better: a fresh look at echinocandin dosing.

Bader JC, Bhavnani SM, Andes DR, Ambrose PG.

J Antimicrob Chemother. 2018 Jan 1;73(suppl_1):i44-i50. doi: 10.1093/jac/dkx448. Review. Erratum in: J Antimicrob Chemother. 2018 Mar 1;73(3):831.

PMID:
29304211
38.

Pharmacodynamics of a Long-Acting Echinocandin, CD101, in a Neutropenic Invasive-Candidiasis Murine Model Using an Extended-Interval Dosing Design.

Lepak AJ, Zhao M, VanScoy B, Ambrose PG, Andes DR.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e02154-17. doi: 10.1128/AAC.02154-17. Print 2018 Feb.

39.

Candida albicans FRE8 encodes a member of the NADPH oxidase family that produces a burst of ROS during fungal morphogenesis.

Rossi DCP, Gleason JE, Sanchez H, Schatzman SS, Culbertson EM, Johnson CJ, McNees CA, Coelho C, Nett JE, Andes DR, Cormack BP, Culotta VC.

PLoS Pathog. 2017 Dec 1;13(12):e1006763. doi: 10.1371/journal.ppat.1006763. eCollection 2017 Dec.

40.

Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats.

Schmitt-Hoffmann AH, Kato K, Townsend R, Potchoiba MJ, Hope WW, Andes D, Spickermann J, Schneidkraut MJ.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01292-17. doi: 10.1128/AAC.01292-17. Print 2017 Dec.

41.

In vivo infection models in the pre-clinical pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents.

Andes DR, Lepak AJ.

Curr Opin Pharmacol. 2017 Oct;36:94-99. doi: 10.1016/j.coph.2017.09.004. Epub 2017 Sep 29. Review.

PMID:
28964956
42.

Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi.

Desai AV, Kovanda LL, Hope WW, Andes D, Mouton JW, Kowalski DL, Townsend RW, Mujais S, Bonate PL.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01034-17. doi: 10.1128/AAC.01034-17. Print 2017 Dec.

43.

The Role of In Vitro Susceptibility Testing in the Management of Candida and Aspergillus.

Ostrosky-Zeichner L, Andes D.

J Infect Dis. 2017 Aug 15;216(suppl_3):S452-S457. doi: 10.1093/infdis/jix239.

PMID:
28911047
44.

Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters.

Lakota EA, Bader JC, Ong V, Bartizal K, Miesel L, Andes DR, Bhavnani SM, Rubino CM, Ambrose PG, Lepak AJ.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e00758-17. doi: 10.1128/AAC.00758-17. Print 2017 Nov.

45.

Thalassosamide, a Siderophore Discovered from the Marine-Derived Bacterium Thalassospira profundimaris.

Zhang F, Barns K, Hoffmann FM, Braun DR, Andes DR, Bugni TS.

J Nat Prod. 2017 Sep 22;80(9):2551-2555. doi: 10.1021/acs.jnatprod.7b00328. Epub 2017 Aug 25.

46.

Distinct roles of the 7-transmembrane receptor protein Rta3 in regulating the asymmetric distribution of phosphatidylcholine across the plasma membrane and biofilm formation in Candida albicans.

Srivastava A, Sircaik S, Husain F, Thomas E, Ror S, Rastogi S, Alim D, Bapat P, Andes DR, Nobile CJ, Panwar SL.

Cell Microbiol. 2017 Dec;19(12). doi: 10.1111/cmi.12767. Epub 2017 Oct 4.

47.

Pharmacodynamic Optimization for Treatment of Invasive Candida auris Infection.

Lepak AJ, Zhao M, Berkow EL, Lockhart SR, Andes DR.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00791-17. doi: 10.1128/AAC.00791-17. Print 2017 Aug.

48.

In Vivo Pharmacodynamic Target Assessment of Eravacycline against Escherichia coli in a Murine Thigh Infection Model.

Zhao M, Lepak AJ, Marchillo K, VanHecker J, Andes DR.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e00250-17. doi: 10.1128/AAC.00250-17. Print 2017 Jul.

49.

Comparative Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh and Lung Infection Models against Staphylococcus aureus.

Lepak AJ, Zhao M, Andes DR.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e00281-17. doi: 10.1128/AAC.00281-17. Print 2017 Jul.

50.

In Vivo Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.

Lepak AJ, Zhao M, VanScoy B, Taylor DS, Ellis-Grosse E, Ambrose PG, Andes DR.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e00476-17. doi: 10.1128/AAC.00476-17. Print 2017 Jun.

Supplemental Content

Support Center